Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-152 Combination Therapy in Cystic Fibrosis
NCT02951195Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VX-152 in cystic fibrosis (CF) (8 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 15 and 1 more. Started Nov 2016; status: completed.
02
Drugs
VX-152
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02951195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951195.